COMMUNIQUÉS West-GlobeNewswire

Vivani Medical, Inc. Announces Pricing of Common Stock Offering
26/01/2026
ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
26/01/2026
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May [...]
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
25/01/2026
First surgeon-reported case using RECELL ® , PermeaDerm ® , and Cohealyx ™ together in a single care pathway New clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness [...]
University Medical Center Southern Nevada Becomes First Hospital in Nevada to Earn Magnet Recognition
24/01/2026
Prestigious designation recognizes excellence in nursing, patient care, and clinical outcomes LAS VEGAS, Jan. 24, 2026 (GLOBE NEWSWIRE) -- University Medical Center Southern Nevada (UMC) has achieved Magnet® designation [...]
Direct Meds NAD+ Injections Consumer Report 2026: Comparing Supplement and Peptide Alternatives, Dosage, Benefits & Side Effects
24/01/2026
A consumer-focused examination of NAD+ injections, NAD+ supplements, NAD+ peptides, NAD+ dosage protocols, documented NAD+ benefits, and potential NAD+ side effects New York, NY, Jan. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Spyre Therapeutics Announces Grants of Inducement Awards
23/01/2026
WALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to [...]
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
23/01/2026
SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/01/2026
BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/01/2026
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
23/01/2026
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ Company ” or “ XTL ”), announced today that it has received a notification letter from The Listing [...]
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
23/01/2026
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to [...]
Synevra UltraLift Ingredients Investigated: 2026 Consumer Analysis Examines Peptide Serum Formula and Dual-Action Skincare System Disclosures
23/01/2026
Independent Analysis Examines Synevra UltraLift SYN-AKE Peptide Complex, VitaLock Beauty Supplement Ingredients, and Company-Reported Formulation Details as Consumer Interest in Anti-Aging Skincare Systems Continues in [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/01/2026
NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Receipt of Delinquency Notification from Nasdaq
23/01/2026
Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company’s [...]
CAPNOS LEGURA Vape Replacement Investigated: 2026 Consumer Analysis Examines Nicotine-Free Behavioral Aid Technology and Safety Documentation
23/01/2026
Independent evaluation explores patent-pending pressurized air throat hit technology, no-heat no-vapor valve mechanism, third-party material safety testing, and oral fixation behavioral science positioning Ann Arbor, MI [...]
MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity
23/01/2026
TOKYO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on Nasdaq: NASDAQ: MRM, hereinafter “MEDIROM”), a company engaged in [...]
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
23/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public [...]
Nexalin Technology Receives Nasdaq Listing Status Notification
23/01/2026
HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today [...]
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
23/01/2026
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business [...]

Pages